Cargando…

605. Identification of a Novel CMY-Variant Enzyme in a Clinical Escherichia coli Strain with Treatment-Emergent Ceftazidime–Avibactam Resistance

BACKGROUND: Ceftazidime–avibactam (CZA) is a novel β-lactam / β-lactamase inhibitor with in vitro activity against multidrug-resistant Gram-negatives, including those harboring CMY-2 enzymes. Treatment-emergent resistance to CZA has been described in KPC-producing Klebsiella pneumoniae but has not b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aitken, Samuel L, Endres, Bradley T, Khan, Ayesha, Shropshire, William C, Borjan, Jovan, Bhatti, Micah M, Sahasrabhojane, Pranoti V, Doi, Yohei, Shields, Ryan K, Shelburne, Samuel A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811110/ http://dx.doi.org/10.1093/ofid/ofz360.674

Ejemplares similares

2246. Improved Outcomes for Cancer Patients Treated With Ceftazidime–Avibactam vs. Polymyxin-Containing Regimens for Carbapenem-Resistant Enterobacteriaceae Bacteremia
por: Borjan, Jovan, et al.
Publicado: (2019)

1055. Epidemiology and Mechanisms of Carbapenem Resistance in Recurrent Extended-Spectrum β-Lactamase- Producing Enterobacteriaceae Bacteremia
por: Aitken, Samuel L, et al.
Publicado: (2018)

2682. Prophylaxis-Driven Molecular Epidemiology of Pseudomonas aeruginosa Bloodstream Infections in Adults With Leukemia
por: Endres, Bradley T, et al.
Publicado: (2019)

Identification and Whole Genome Sequencing of the First Case of Kosakonia radicincitans Causing a Human Bloodstream Infection
por: Bhatti, Micah D., et al.
Publicado: (2017)

60. Creation and Comparison of a Machine Learning Decision Tree and Traditional Risk Score to Predict Ceftriaxone Resistance in Cancer Patients with E. coli Bacteremia
por: Moc, Courtney, et al.
Publicado: (2021)

305. Prevalence of Ceftriaxone Susceptible, Piperacillin-tazobactam Non-susceptible Escherichia coli Bacteremia in Patients with Hematologic Malignancy
por: Spitznogle, Sarah L, et al.
Publicado: (2020)

2674. Microbiome and Cumulative Antibiotic Use as Predictors of Stenotrophomonas maltophilia Infection in Patients with Acute Myeloid Leukemia Receiving Remission-Induction Chemotherapy
por: Aitken, Samuel L, et al.
Publicado: (2019)

1831. Machine Learning Approaches to Predicting Resistance in Pseudomonas aeruginosa
por: Greenberg, David E, et al.
Publicado: (2019)

1009. Venous 1: A Prospective Multicenter Cohort Study of Enterococcal Bacteremia
por: Contreras, German, et al.
Publicado: (2018)

622. The Accessory Genome in Enterococcal Bacteremia: Results from the Vancomycin-Resistant Enterococcal Bacteremia Outcomes Study (VENOUS)
por: Simar, Shelby, et al.
Publicado: (2019)

Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms
por: Khan, Ayesha, et al.
Publicado: (2021)

735. Contribution of the Oral Cavity and Gastrointestinal Microbiome on Bloodstream Infections inLeukemia Patients
por: McMahon, Stephanie, et al.
Publicado: (2022)

Oral and Stool Microbiome Coalescence and Its Association With Antibiotic Exposure in Acute Leukemia Patients
por: Franklin, Samantha, et al.
Publicado: (2022)

2451. Synergistic Activity of Ceftazidime–Avibactam in Combination With Polymyxin B Against Carbapenem-Resistant Klebsiella pneumoniae
por: Borjan, Jovan, et al.
Publicado: (2018)

A Novel CMY Variant Confers Transferable High-Level Resistance to Ceftazidime-Avibactam in Multidrug-Resistant Escherichia coli
por: Zhou, Junxin, et al.
Publicado: (2023)

9. Evaluation of Synergy Testing Methods for Clinical Labs to Determine Susceptibility of Extensively Drug-resistant Gram-negatives to Ceftazidime/ Avibactam and Aztreonam Combination Therapy
por: Khan, Ayesha, et al.
Publicado: (2020)

Dual-Site Phosphorylation of the Control of Virulence Regulator Impacts Group A Streptococcal Global Gene Expression and Pathogenesis
por: Horstmann, Nicola, et al.
Publicado: (2014)

A Combination of Independent Transcriptional Regulators Shapes Bacterial Virulence Gene Expression during Infection
por: Shelburne, Samuel A., et al.
Publicado: (2010)

Streptococcus mitis Strains Causing Severe Clinical Disease in Cancer Patients
por: Shelburne, Samuel A., et al.
Publicado: (2014)

Ceftazidime-avibactam
por: Matesanz, Mayra, et al.
Publicado: (2021)

Ceftazidime-avibactam
por: Herrero, Francisco Sanz
Publicado: (2022)

2248. Clinical and Microbiological Outcomes Associated with Real-World Use of Ceftolozane/Tazobactam
por: Cabrera, Nicolo, et al.
Publicado: (2019)

Complete Genome Sequence of Streptococcus mitis Strain SVGS_061 Isolated from a Neutropenic Patient with Viridans Group Streptococcal Shock Syndrome
por: Petrosyan, Varduhi, et al.
Publicado: (2016)

Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia
por: Robinson, Sarah, et al.
Publicado: (2020)

Activity of Cefiderocol and Comparators against Isolates from Cancer Patients
por: Rolston, Kenneth V. I., et al.
Publicado: (2020)

Temporal dynamics of genetically heterogeneous extended-spectrum cephalosporin-resistant Escherichia coli bloodstream infections
por: Shropshire, William C., et al.
Publicado: (2023)

1844. Mortality associated with Stenotrophomonas maltophilia bloodstream infection in patients with leukemia
por: Aitken, Samuel L, et al.
Publicado: (2022)

Distinct Single Amino Acid Replacements in the Control of Virulence Regulator Protein Differentially Impact Streptococcal Pathogenesis
por: Horstmann, Nicola, et al.
Publicado: (2011)

1298. Population Pharmacokinetics of Ceftazidime-avibactam among Critically-ill Patients with and without Receipt of Continuous Renal Replacement Therapy
por: Kline, Ellen G, et al.
Publicado: (2020)

Ceftazidime/avibactam for specified infections
Publicado: (2020)

125 Single Nucleotide Polymorphisms Drive Phenotypic Diversity Among Sequence Type 1 Group B Streptococcus, An Emerging Cause of Invasive Disease in Adult Humans
por: Galloway-Pena, Jessica, et al.
Publicado: (2014)

Contribution of the Oral and Gastrointestinal Microbiomes to Bloodstream Infections in Leukemia Patients
por: McMahon, Stephanie, et al.
Publicado: (2023)

Acetylcysteine increases sensitivity of ceftazidime-avibactam–resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo
por: Huang, Zeyu, et al.
Publicado: (2023)

2398. Utilization Practices of Ceftazidime–Avibactam at Academic Medical Centers in the United States
por: Strich, Jeffrey R, et al.
Publicado: (2018)

2254. Multicenter Evaluation of Ceftazidime–Avibactam for Multidrug-Resistant Pseudomonas aeruginosa Infections
por: Jorgensen, Sarah C J, et al.
Publicado: (2019)

2379. Multicenter Evaluation of Ceftazidime–Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections
por: Jorgensen, Sarah, et al.
Publicado: (2018)

273. Comparative Effectiveness of Ampicillin in the Treatment of Enterococcus faecalis Bloodstream Infections in Patients With Cancer
por: Sanchez, J P, et al.
Publicado: (2020)

Clinical Outcomes Associated With Linezolid Resistance in Leukemia Patients With Linezolid-Resistant Staphylococcus epidermidis Bacteremia
por: Folan, Stephanie A, et al.
Publicado: (2018)

Prophylactic Antibiotic Therapy and Blood Stream Infections in Leukemia Patients Presenting to the Emergency Center
por: Jandhyala, Deeksha, et al.
Publicado: (2017)

Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections
por: Jorgensen, Sarah C J, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_aa3jdg8duvj4ncj22khaaqg0iv